US FDA grants priority review status to Allergan ’s sNDA for Avycaz

The US Food and Drug Administration (FDA) has granted priority review status for Allergan ’s supplemental New Drug Application (sNDA) for Avycaz (ceftazidime and avibactam) to treat hospital-acquired bacterial pneumonia / ventilator-associated bacteri…
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news